SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million
SenzaGen’s interim report January–March 2026 | 10% sales growth alongside increased attention to non-animal methods
SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners
